NCT00477542已完成1 期
A Phase I Trial of Myeloablative Conditioning Using Clofarabine and High-Dose Busulfan for Patients With Refractory Hematological Malignancies Undergoing Allogeneic HSCT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Determine the MTD of clofarabine in association with a myeloablative dose of busulfan as a preparative regimen in patients with refractory hematological malignancies undergoing allogeneic HSCT.
研究概览
简要总结
This is a phase trial to determine the maximum tolerated dose (MTD) of clofarabine in a combination with a myeloablative dose of busulfan. This is an initial step in developing a novel myeloablative preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT). While this phase I trial will initially develop the regimen in patients with refractory disease, it is expected that it will find its best application in patients with less advanced disease
详细描述
All patients will receive the same dose of busulfan. The dose of clofarabine will be escalated in successive cohorts of patients. Using a standard dose escalation design, successive cohorts of 3 patients will be treated with escalating doses of clofarabine. At the MTD (or highest dose-level if the MTD is not reached), the cohort will be expanded to 10 patients to better investigate correlative studies and give some preliminary idea of efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documentation of disease. Patients must have one of the following disease types:
- •Acute myeloid leukemia (AML) with either:
- •Primary refractory to induction chemotherapy
- •Relapsed and refractory AML with >5% blasts in bone marrow or extramedullary disease (excluding active disease of the central nervous system).
- •Patients in second or subsequent complete remission (CR2, CR3, etc.).
- •Acute lymphoblastic leukemia (ALL) with one of the following criteria:
- •Primary refractory to induction chemotherapy.
- •Relapsed and refractory ALL with >5% blasts in bone marrow or extramedullary disease (excluding active disease of the central nervous system).
- •Patients in second or subsequent complete remission (CR2, CR3, etc.).
- •Myelodysplasia, refractory anemia with excess blasts with 11-20% blasts in the bone marrow (RAEB II).
- •Chronic myelogenous leukemia (CML) with one of the following criteria:
- •Accelerated phase.
- •Patients in blast crisis.
- •Patients with aggressive non-Hodgkin's lymphoma (NHL), including diffuse large cell lymphoma, mediastinal B-cell lymphoma, transformed lymphoma, mantle cell lymphoma, and peripheral T cell lymphoma, who also have one of the following criteria:
- •Failure to achieve complete remission to primary induction therapy
- •Relapsed NHL, refractory to at least one line of salvage systemic therapy
- •Patients who relapse < 6 months following autologous stem cell transplantation are not eligible.
- •Patient age 18-60 years
- •Availability of a consenting HLA-matched donor
- •Performance status ECOG 0-1
- •No active infection. Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection.
- •No HIV disease. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies.
- •Non-pregnant and non-nursing. Treatment under this protocol would expose a fetus to significant risks. Women of childbearing potential should have a negative pregnancy test prior to study entry. Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (Norplant®), or double barrier method (diaphragm plus condom).
- •Required baseline laboratory values:
- •LVEF > 45% corrected
- •DLCO > 50% of predicted value (corrected for hemoglobin)
- •Serum creatinine ≤ 2.0 mg/dl or estimated creatinine clearance of ≥60 ml/min
- •Bilirubin < 1 x upper limit of normal value
- •AST and ALT < 1 x upper limit of normal value
- •Signed written informed consent. Patient must be capable of understanding the investigational nature of the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
排除标准
- •Patients who relapse < 6 months following autologous stem cell transplantation are not eligible
结局指标
主要结局
Determine the MTD of clofarabine in association with a myeloablative dose of busulfan as a preparative regimen in patients with refractory hematological malignancies undergoing allogeneic HSCT.
时间窗: 1 year
次要结局
- • Assessment of the toxicity of the combination of clofarabine and busulfan • Assess clofarabine and busulfan pharmacokinetics with combination therapy • Describe the response rate • Describe relapse rate and event-free survival(1 year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHLNon Hodgkin's LymphomaNCT00477945Indiana University School of Medicine18
终止
1 期
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasAcute Promyelocytic LeukemiaMyeloproliferative DisordersAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeAcute LeukemiaChronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaMyelofibrosisJuvenile Myelomonocytic LeukemiaNCT00852709Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35
已完成
1 期
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic LeukemiaAcute Lymphoid Leukemia RelapseAcute Lymphoid Leukemia Relapse After Bone Marrow TransplantNCT01279096University Hospital, Lille20
撤回
1 期
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaLeukemiaNCT00800566M.D. Anderson Cancer Center
已完成
1 期
Clofarabine in High Risk Myelodysplastic Syndrome (MDS)Myelodysplastic SyndromeNCT01063257Groupe Francophone des Myelodysplasies76